Hence, exploring novel mechanisms regulating PD-L1 expression and identifying pharmaceutical agents that modulate PD-L1 expression holds immense importance for the clinical management of GC and enhances prognostic outcomes among GC patients. Here, CD274 is linked to gastric cancer.